BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• 

  Legal

  Novo Seeks $830M in Fraud Case Against Singaporean Biotech Over Kidney Drug

  Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences. Now, the pharma giant claims to have been misled by the biotech’s founder—and a judge seems to agree.

  February 18, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Rare diseases

  Biogen and Stoke Strike Dravet Syndrome Co-Development Deal

  The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential payments due to Stoke.

  February 18, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Podcast

  A Conversation With Dannielle Appelhans, CEO of COUR

  In the first podcast in a special series focused on BioSpace’s NextGen Class of 2025, Senior Editor Annalee Armstrong speaks with Dannielle Appelhans, CEO of COUR.

  February 18, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Cancer

  Arcus Challenges Merck in Kidney Cancer with Early Data

  Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, according to analysts at Truist Securities.

  February 18, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pain

  AlgoTx Stumbles in Non-Opioid Pain Trial Following Vertex’s Journavx Approval

  AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still believes in the promise of its candidate as Vertex Pharmaceuticals’ first-in-class drug Journavx opens up the non-opioid space.

  February 18, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  NextGen

  After 10 Years of Hard Work, COUR Treads Into Pharma’s Myasthenia Gravis Territory

  COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise.

  February 18, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• Press Releases

  Shift Bioscience Establishes North American Facilities to Expand Capabilities of AI-Powered Virtual Cell Technology

  February 18, 2025

   · 

  3 min read
• Press Releases

  Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

  February 18, 2025

   · 

  11 min read
• Press Releases

  Teleflex to Present at the Raymond James & Associates 46th Annual Institutional Investors Conference

  February 18, 2025

   · 

  1 min read
• Press Releases

  Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

  February 18, 2025

   · 

  4 min read